Fecal microbiota-based treatment for recurrent Clostridioides difficile infection.
Where this comes from
- Record sourced from PubMed, PMID 36931236.
- Also identified by DOI 10.1016/j.cell.2023.02.034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rebyota is a rectally administered fecal microbiota suspension for prevention of recurrence of Clostridioides difficile infection. The mechanism of action of Rebyota probably involves competitive exclusion of C. difficile by donor microbes with reduced toxin production; other factors may include restoration of protective taxa and modulation of the recipient's microbiome by phage, donor microbes, or metabolites.
Medical subject headings
- Clostridioides difficile
- Clostridium Infections
- Microbiota